Kopernik Global Investors LLC Invests $19.66 Million in Humana Inc. $HUM

Kopernik Global Investors LLC purchased a new position in Humana Inc. (NYSE:HUMFree Report) during the 1st quarter, HoldingsChannel.com reports. The fund purchased 113,385 shares of the insurance provider’s stock, valued at approximately $19,660,000. Humana comprises approximately 1.4% of Kopernik Global Investors LLC’s portfolio, making the stock its 21st biggest position.

Other hedge funds have also recently bought and sold shares of the company. Montag A & Associates Inc. raised its position in shares of Humana by 1,880.0% in the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock valued at $25,000 after purchasing an additional 94 shares in the last quarter. CoreCap Advisors LLC increased its stake in shares of Humana by 54.4% in the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after buying an additional 37 shares during the last quarter. Fideuram Asset Management Ireland dac bought a new stake in shares of Humana in the fourth quarter worth $27,000. Reflection Asset Management acquired a new stake in Humana in the fourth quarter valued at $29,000. Finally, Global Assets Advisory LLC acquired a new stake in Humana in the first quarter valued at $38,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Analysts Set New Price Targets

HUM has been the subject of several recent analyst reports. Mizuho raised their price objective on shares of Humana from $335.00 to $390.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. Sanford C. Bernstein restated an “outperform” rating and issued a $425.00 target price on shares of Humana in a research note on Wednesday, June 3rd. Truist Financial increased their price target on shares of Humana from $320.00 to $415.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Needham & Company LLC initiated coverage on Humana in a research note on Wednesday, May 20th. They issued a “buy” rating for the company. Finally, The Goldman Sachs Group boosted their price objective on Humana from $158.00 to $195.00 and gave the company a “sell” rating in a report on Thursday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Humana currently has an average rating of “Hold” and an average price target of $327.17.

Check Out Our Latest Research Report on HUM

Humana Stock Performance

Shares of HUM opened at $397.93 on Thursday. The firm has a fifty day moving average of $360.55 and a 200-day moving average of $263.22. The company has a market cap of $47.78 billion, a price-to-earnings ratio of 42.56, a price-to-earnings-growth ratio of 2.20 and a beta of 0.71. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.77 and a current ratio of 1.77. Humana Inc. has a 1 year low of $163.11 and a 1 year high of $428.88.

Humana (NYSE:HUMGet Free Report) last released its quarterly earnings data on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share for the quarter, topping analysts’ consensus estimates of $9.97 by $0.34. The business had revenue of $39.65 billion for the quarter, compared to analysts’ expectations of $39.37 billion. Humana had a net margin of 0.82% and a return on equity of 10.45%. The company’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same quarter last year, the company earned $11.58 EPS. Humana has set its FY 2026 guidance at 9.000- EPS. As a group, equities analysts anticipate that Humana Inc. will post 9.46 earnings per share for the current year.

Humana Profile

(Free Report)

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

Recommended Stories

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMFree Report).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.